AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...

AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...